Contact Us

Phone: 1-866-61-EISAI (1-866-61-34724)

Fax: 1-866-57-EISAI (1-866-57-34724)

Monday - Friday 8AM - 8PM ET


Eisai is committed to supporting patient access by helping with your reimbursement questions. With this in mind, the ALOXI® (palonosetron HCI injection) Reimbursement site has been designed to provide healthcare professionals with information related to the insurance reimbursement environment for ALOXI®.

Indication in Adults

ALOXI® injection 0.25 mg is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and the prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.

Indication in Pediatrics

ALOXI® injection 20mcg/kg (max 1.5mg) is indicated in patients ≥ 1 month up to 17 years of age, for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic chemotherapy.

Important Safety Information:


  • ALOXI® is contraindicated in patients known to have hypersensitivity to the drug or any of its components

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, have been reported with or without known hypersensitivity to other 5-HT3 receptor antagonists
  • Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone, but particularly with the use of serotonergic drugs. Serotonin syndrome can be life threatening. Symptoms may include the following combination of signs and symptoms: mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms. Patients should be monitored for the emergence of serotonin syndrome, and if symptoms occur, discontinue ALOXI® and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if ALOXI® is used concomitantly with other serotonergic drugs.

Adverse Reactions

  • In pediatric patients, while they require a higher dose of palonosetron, the safety profile is consistent with the established profile in adults; however, adverse reactions were reported in < 0.1% of pediatric patients
  • In adults, the most commonly reported adverse drug reactions include headache (9%) and constipation (5%)

For more information about ALOXI®, please see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payer, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. For additional information, customers should consult with their payers for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries. This site is published by Eisai Inc.

ALOXI® is a registered trademark of Helsinn Healthcare SA, Switzerland, used under license.

Distributed and marketed by Eisai Inc. ALOX-0001 ©2015 Eisai Inc. All rights reserved.

This site was last modified on : September 25, 2015 at 2:45 PM EST.